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Lysosomal storage disordersAbstract Background: Inborn errors of metabolism (IEM) are single gene disorders responsible
for abnormalities in the synthesis or catabolism of proteins, carbohydrates and fats by means of
defective enzymes or transport proteins which results in a block of the metabolic pathway and
accumulation of metabolites in different tissues. This study shows the most common diagnosed
inherited inborn errors of metabolism among the Egyptian population. Prior to 1995, the diagnosis
of inherited metabolic disorders in Egypt was very limited and diagnosed mainly on clinical suspi-
cion. In 1995, The Biochemical Genetics Unit at The National Research Centre has been established
as a part of The Human Genetics Department and later on in 2003 it was developed into The
Biochemical Genetics Department by applying advanced techniques and equipments and providing
early diagnosis for the metabolic disorders which led to better outcome in our patients.
Material and methods: We have retrospectively reviewed a total of 12,148 cases suspected to have
inborn errors of metabolism (IEM) with different age groups. They had been referred from several
diagnostic centers and hospitals in Egypt to The Department of Biochemical Genetics at The
National Research Centre. The diagnosis of these disorders was conﬁrmed by qualitative determi-
nation of amino acid proﬁle, quantitative determination of phenylalanine and galactose levels using
dried blood spots (DBSs), quantitative determination of urinary glycosaminoglycans (GAGs), two-
dimensional electrophoretic separation of GAGs in urine and the assay for lysosomal enzymes
activities in plasma and leukocytes.
Results: Out of the total number of cases; 1041 (8.6%) patients were proved to have metabolic
disorders. Those patients were classiﬁed as: 722 patients (69.4%) with lysosomal storage disorders,
302 patients (29%) with amino acid disorders and 17 patients (1.6%) with galactosemia.
Conclusion: This study illustrates the experience of the reference metabolic lab in Egypt over
15 years. The lab began metabolic disorder screening by using simple diagnostic techniques like thin
layer chromatography and colored tests in urine which by time updated and upgraded the methods
to diagnose a wide range of disorders. This study shows the most common diagnosed inherited
inborn errors of metabolism among the Egyptian population.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Inherited metabolic diseases are a group of genetic disorders
characterized by speciﬁc enzymatic defects leading to accumu-
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pathologic sequels. The detection of metabolic disorder is done
either by measuring the enzyme activities or detection and
quantiﬁcation of the abnormal metabolites by different avail-
able techniques.
Aminoacidopathies are a class of inborn errors of metabo-
lism where an enzyme defect inhibits the ability of the body to
metabolize certain amino acids. They are autosomal recessive
diseases; each of them has a certain characteristic. Early detec-
tion of these disorders by quantitation of the amino acids in
question leads to early treatment and is either life saving for
many newborns or prevents serious sequelae of the disease
e.g. mental retardation in case of phenylketonuria (PKU) [1].
Lysosomal storage diseases are a group of inherited metabolic
disorders, resulting from a defect in one of the lysosomal catabolic
enzymes. They all lead to physical and mental sequelae. Proper
diagnosis of these disorders will help to give proper counseling
and treatment to the affected siblings and offer prenatal diagnosis
to avoid the birth of other affected children in subsequent pregnan-
cies. Also, carrier detection among family members will help
proper counseling and avoid birth of further affected children.
Historically, the lysosomal storage diseases were classiﬁed
on the bases of their storage products, e.g. lipidoses, muco-
polysaccharidoses, glycoproteinoses and glycogen storage dis-
ease. This categorization brought together diseases with
common symptoms reﬂecting disturbances in the lysosomal
catabolic pathway for a particular group of metabolites.
Mucopolysaccharidoses comprise a group of inherited met-
abolic diseases caused by the deﬁciency of lysosomal enzymes
needed to break down glycosaminoglycans which are long
chains of sugar carbohydrates present in cells of bone, carti-
lage, tendons, corneas, skin and connective tissue. Glycosami-
noglycans (formerly called mucopolysaccharides) are also
found in the synovial ﬂuid that lubricates our joints. Patients
with mucopolysaccharidoses either do not produce enough
of one of the 11 enzymes required to break down these sugar
chains into proteins and simpler molecules or they produce
enzymes that do not function properly. By time, these glycos-
aminoglycans accumulate in the cells and connective tissues.
The result is permanent progressive cellular damage that
affects the individual’s appearance, physical abilities, organ
system functioning and in most cases mental development [2].
Sphingolipidoses are deﬁned as a group of lysosomal disor-
ders leading mainly to organomegaly due to accumulations of
sphingolipids in macrophages of the reticuloendothelial system
cells. Sphingolipids are found all over the body but are of spe-
cial importance in the nervous tissue. Galactocerebrosides, sul-
fatides and sphingomyelins are essential components of the
myelin sheath gangliosides. They are found particularly in the
grey matter of the brain. Clinical features include progressive
psychomotor retardation and neurological problems especially
convulsions as well as ataxia. They include: GM1 Gangliosido-
sis, Tay Sachs, Sandhoff, Metachromatic leukodystrophy, Nie-
mann–Pick disease, Gaucher disease and Krabbe disease [3].
2. Patients and methods
2.1. Patients
This study includes 12,148 cases referred to the Biochemical
Genetics laboratory at the National Research Centre (NRC)during the period from January 1995 to December 2010. They
were suspected to have metabolic disorders and their ages ran-
ged from 1 day to 20 years. For the determination of amino
acid proﬁle, 5–10 ml urine and 1–2 ml heparinized plasma were
collected. Blood spots from a heel prick on ﬁlter paper were col-
lected for the determination of phenylalanine and total galact-
ose levels in blood. For the determination of level of urinary
GAGs and their two-dimensional electrophoretic separation
about 5 ml urine was collected. Five ml heparinized whole blood
was collected for the separation of white blood cells and mea-
suring activity of the deﬁcient enzymes speciﬁc for each disorder
ﬂuorometrically. A written informed consent was obtained from
all parents of the included patients after full explanation of the
study. The ethical approval was obtained from the medical eth-
ics committee at the National Research Center.
2.2. Methods
Methods used throughout this work for the diagnosis of the
different metabolic disorders included:
n Qualitative determination of amino acid proﬁle by Thin
layer chromatographic separation (TLC) in urine and
plasma according to the procedure described by Borden
in 1984 [4]. Urine and plasma samples were applied on
sheets of cellulose plates on an aluminum foil. The ﬁrst
phase of development included a mobile phase in the form
of a mixture of acetone, butanol, acetic acid and water
while the second phase had a mobile phase with the same
composition in addition to ninhydrin dye.
n Quantitative determination of phenylalanine and total gal-
actose levels in dried blood spot (DBS) according to Slazyk
and Hannon [5]: The determination is based on punching a
1/8 inch diameter disc from DBS into polymicrotiter plate,
then elution buffer was added and shacked for 30 min. The
discs were removed using vacuum manifold. The working
reagent was added to each well and shacked for 30 min
and then coloring reagent was added and the absorbance
was read at dual wave length 570/690 nm.
n Quantitative determination of total urinary glycosamino-
glycans (GAGs) according to De Jong et al. [6]: The deter-
mination is based on the reaction of GAGs with
dimethylmethylene blue dye (DMB) yielding a colored com-
plex that can be measured spectrophotometrically at
k= 520 nm. GAG concentration (mg/dl) was subsequently
normalized to urinary creatinine concentrations to yield
ﬁnal reported values of GAG concentrations in units of
mg/mmol creatinine.
n Two-dimensional electrophoretic separation of total uri-
nary GAGs according to Hopwood and Harrison method
[7].
Alcian blue was added to centrifuged urine (alcian blue + -
GAGs will form complex), followed by the addition of 4 M
NaCl, methanol, then 0.1 M sodium carbonate and water. This
leads to the dissociation of the complex and formation of
alcian blue precipitates. A clear supernatant was transferred
to a conical tube, and ethanol was added and centrifuged, then
decanted. The precipitate was dried in a small oven and stored
at room temperature. Extracted GAGs were applied onto
cellulose acetate sheets. In the ﬁrst run; the buffer used was
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(0.1 M) Barium acetate. Run time was 3 h. The GAGs were
stained by the immersion of the cellulose acetate sheets in
alcian blue dye, washed with 5% acetic acid; leaving GAGs
present as blue spots.
n Assay of lysosomal enzymes according to methods of Hall
et al. [8]:
Principle of enzyme assay:
Leucocyte enzymes: Substrate is added to leukocyte
homogenate. The tubes are sealed, covered and incubated.
The reaction is stopped with a stopping solution. The tubes
are shacked brieﬂy and read ﬂuorometrically or calorimet-
rically according to the used substrate.
Plasma enzymes: Substrate is added to plasma. The tubes
are sealed, covered and incubated. The reaction is stopped
with a stopping solution. The tubes are shacked brieﬂy and
read ﬂuorometrically.
The work has been carried out in accordance to the Decla-
ration of Helsinki.
3. Results
This study included a total number of 12,148 cases suspected
to have metabolic disorders with age ranging from 1 day to
20 years and of which 8998 cases (74%) showed positive paren-
tal consanguinity (Fig. 1). Of this number, 5985 cases were sus-
pected to have amino acid disorders, 694 cases to have
galactosemia and the remaining 5469 cases were suspected to
have lysosomal storage diseases. Out of the total enclosed
cases, 1041 (8.6%) cases were proved to have a metabolic dis-
order. Those patients were classiﬁed as: 722 patients (69.4%)
with lysosomal storage disorders, 302 patients (29%) with
amino acid disorders and 17 patients (1.6%) with galacto-
semia. Fig. 2 represents the types and percentage of metabolic
disorders diagnosed during the period from 1995 to 2010.
4. Discussion
Inherited metabolic disorders are a heterogeneous group of
genetic conditions mostly diagnosed in childhood and causingFigure 1 Carbohydrate disorders diagnosed in The Biochemical
Genetics laboratory at The National Research Centre during the
period from 1995 to 2010.substantial morbidity and mortality. This study represents ﬁf-
teen years experience of biochemical diagnosis for the inherited
metabolic disorders at The Biochemical Genetics Department
as the main reference lab in Egypt. We have retrospectively
reviewed a total of 12,148 cases suspected to have inborn
errors of metabolism with different ages who had been referred
from several diagnostic centers and hospitals.
This number includes; amino acid disorders, galactosemia
and lysosomal storage disorders however organic acidemias
were not included since they are recently diagnosed in our
lab and were not established ﬁfteen years ago.
Most of the metabolic disorders are autosomal recessive
and the incidence of the majority of IEM was high among
the included cases. This was due to the high consanguinity rate
which was evidenced during collecting data of the subjects and
represents about three quarters of the referred cases. Temtamy
and Loutife in 1970 stated that the rate of marriage between
relatives among the studied Egyptian people was 33% [9]
and it was 28.9% in the study done by Hafez et al. in 1983
[10]. In another study performed in 2010 by Temtamy et al.,
they recorded a rate of about 40% consanguineous marriages
[11], while it was 35.3% in the study done by Shawky et al.
[12].
Five thousand nine hundred eighty-ﬁve were referred to our
lab to perform metabolic screening for the amino acids in
plasma and urine. The analysis revealed the presence of a large
number of cases with generalized aminoaciduria as shown in
Table 1 which in most cases result from certain drug adminis-
trations such as antibiotics especially penicillin, drugs contain-
ing amino acid like N-acetylcysteine, or drugs with sulfur
content like 2-mercaptoethanesulfonate or from change in
urine pH or from bacterial contamination [13] as their clinical
condition did not ﬁt with any of the known aminoacidopathies
(Table 2).
4.2. Aminoacidopathies
4.2.1. Phenylketonuria (PKU)
Phenylketonuria (PKU) is one of the neurogenetic disorders
which was ﬁrst diagnosed in 1934 [14] and it is considered
one of the most common IEM with the highest incidence inFigure 2 Type and percentage of 1041 patients with metabolic
disorders diagnosed in The Biochemical Genetics Laboratory at
The National Research Centre from 1995 to 2010.
Table 1 Amino acid disorders diagnosed in The Biochemical Genetics laboratory at The National Research Centre during the period
from 1995 to 2010.
Number of suspected cases Number of positive cases Amino acid disorders
5985 302 (5.04% out of 5985) Generalized aminoaciduria 171 (56.6%)
Phenylketonuria (PKU) 94 (31.1%)
Tyrosinemia 22 (7.3%)
Maple syrup urine disease (MSUD) 12 (4%)
Nonketotic hyperglycemia 3 (1%)
Table 2 Lysosomal storage disorders diagnosed in The Biochemical Genetic laboratory at The National Research Centre during the
period from 1995 to 2010.
Number of
suspected cases
Number of positive cases Diseases
5469 722 (13.2% out of 5469) Gaucher disease (GD) 202 (28%)
Metachromatic leukodystrophy (MLD) 94 (13%)
Tay sachs disease 33 (4.6%)
Niemann–Pick disease 32 (4.4%)
Sandhoﬀ disease 8 (1.1%)
Mucopolysaccharidoses (MPS): 353 (48.9%)
MPS Type I (Hurler Syndrome) 100 (28.3%)
MPS Type VI (Maroteaux–Lamy) 83 (23.5%)
MPS Type IV (Morquio Syndrome) 75 (21.3%)
MPS Type III (Sanﬁlippo Syndrome)
(22 patients with MPS type III B)
61 (17.3%)
MPS Type II (Hunter Syndrome) 34 (9.6%)
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ketonuria simple screening tests in urine such as Ferric chlo-
ride (Fecl3) and Dinitrophenylhydrazine (DNPH) tests were
done [16]. In the 94 patients proved to have Phenylketonuria,
Ferric chloride test in urine gave green color indicating the
presence of phenylpyruvic in high concentration and the
DNPH test gave positive results in the form of clouding and
yellow precipitate indicating the presence of a-ketoacids. By
performing thin layer chromatographic separation (TLC) of
free amino acids in plasma and urine a distinguishable band
of phenylalanine amino acid was clear. The cases were con-
ﬁrmed to have PKU by quantitative estimation of phenylala-
nine level in dried blood spot [6]. The phenylalanine amino
acid levels in blood were found to be elevated in the 94 cases
(9% out of 1041 patients with metabolic disorders). The mea-
surement of the amount of the amino acid in blood was a use-
ful tool for monitoring the diagnosed patients who were on
diet restriction or on BH4 therapy. About 1/3 of diagnosed
cases with aminoacidopathies were conﬁrmed to have PKU
which is relatively a high number, so early diagnosis followed
by early treatment of phenylketonuria is essential and mass
screening programs for the disease are recommended.
4.2.2. Maple syrup urine disease (MSUD)
Another multi-system degenerative and rapidly progressive
IEM is MSUD with a worldwide frequency of 1/185,000 live
newborns [17]. It is caused by a defect in the branched chain
a-ketoacid dehydrogenase complex. The clinical manifesta-
tions are due to the accumulation of both branched-chain
amino acids (BCAAs) and branched-chain a-ketoacids [18].
In the included cases, this devastating aminoacidopathy was
diagnosed in 12 cases [(12/1041 (1.2%)] which constitutes4% out of 302 patients proved to have aminoacidopathy. This
was done by performing thin layer chromatographic separa-
tion of amino acids in plasma and urine which revealed the
abnormal abundance of branched chain amino acids (valine,
leucine, and isoleucine). In addition to positive DNPH test
due to presence of high amounts of ketone bodies [19].
4.2.3. Tyrosinemia
Hepatorenal tyrosinemia (tyrosinemia type I) is an autosomal
recessive inborn error of metabolism due to a deﬁciency of
fumarylacetoacetate hydrolase leading to accumulation of
fumarylacetoacetate and succinylacetone. It is usually asymp-
tomatic in newborns, but if left untreated it affects liver, kid-
ney, bone, and peripheral nerves; The incidence of this
condition is estimated to be 1:100,000 but may be much higher
in certain populations such as the province of Quebec, where it
is 1: 20,000 live births [20]. Twenty-two cases [22/1041 (2.1%)]
represent 7.3% out of 302 cases diagnosed to have aminoacid-
opathies. TLC separation of free amino acids in urine and
plasma of those patients showed a band of Tyrosine and Nitr-
osonaphthol test in their urine gave positive results indicating
the presence of Tyrosine. In the study of Shawky and Nour El-
Din in 2012 [21], they stated that transient neonatal tyrosine-
mia was detected in 0.05% of cases screened for IEM.
4.2.4. Nonketotic hyperglycinemia (NKH)
Glycine encephalopathy, which is also known as nonketotic
hyperglycinemia (NKH) is a genetic disorder characterized
by abnormally high levels of glycine. The worldwide incidence
of glycine encephalopathy is unknown. Its frequency has been
studied in only a few regions: this condition affects about 1 in
55,000 newborns in Finland and about 1 in 63,000 newborns in
Fifteen years experience 383British Columbia, Canada [22]. In this study, only 3 patients
(3/1041 0.3%) gave a band of glycine in TLC separation of free
amino acids in urine and blood and this represents 1% out of
302 cases diagnosed with aminoacidopathy. In a previous
Egyptian study, it was reported that two cases had non-ketotic
hyperglycinemia out of a total number of 51 cases conﬁrmed to
be positive for IBM during a general screening program in
2001 [23].
Recently we are using more advanced methods to conﬁrm
the diagnosis of aminoacidopathies and lipid metabolism dis-
orders. Liquid chromatography mass spectrometry (LC–MS/
MS) for performing quantitative estimation of amino acids
proﬁle and acylcarnitines in dried blood spots as well as qual-
itative estimation of organic acids in urine using Gas chroma-
tography mass spectrometry [24]. Early diagnosis and
management and early starting of dietary intervention of
aminoacidopathies are essential to prevent complications and
permanent brain damage and may allow for normal intellec-
tual development. Expanded Tandem MS allows for the detec-
tion of elevated amino acids and acylcarnitines concentrations
in blood which helps in New Born Screening Program (NBS)
for aminoacidopathies as it is recommended in our country.
4.3. Galactosemia
Hereditary galactosemia is among the most common carbohy-
drate metabolism disorders and can be a life-threatening illness
during the newborn period. It was ﬁrst described in a variant
patient in 1935 by Mason and Turner [25] who stated that gal-
actose-1-phosphate uridyltransferase (GALT) deﬁciency is the
most common enzyme deﬁciency that causes increased level of
total galactose in blood [26]. Its incidence widely varies as it is
1:70,000 people in the UK, 1:20,000 people in Ireland while in
the United States the incidence is approximately 1:40,000–
60,000 persons [25]. The disorder is thought to be much less
common in Asians. Seventeen patients out of the 694 suspected
cases were diagnosed to have Galactosemia (2.44%) by quan-
titative measurements of total galactose and glactose-1-P in
dried blood spots. The early diagnosis and early dietary inter-
vention for galactosemia patients will save the lives of those
patients with this treatable metabolic disorder and prevent
long term complications so as to reduce the burden on their
families and government. Hence, many countries included this
disorder in their NBS programs.
4.4. Lysosomal storage disorders
Lysosomal storage disorders are genetic disorders in which the
lysosomal metabolism of many macromolecules is impaired
leading to accumulation of many substances inside the cells
leading to their swelling which in turn results in organomegaly
with improper functioning of the involved systems. The inci-
dence of their occurrence ranges from 1:5000 to 1:7000 new-
borns [3]. This class of IEM comprises the defect in
metabolism of sphingolipids, mucopolysaccharides, oligosac-
charides and lysosomal transport defects [2]. Sphingolipidoses
make up about one half of the number of patients diagnosed
with lysosomal storage diseases including metachromatic leu-
kodystrophy (MLD), Gaucher disease (GD), Niemann pick
disease (NPD), GM2-Gangliosidosis and Krabbe disease [27].4.4.1. Metachromatic Leukodystrophy (MLD)
It is due to the deﬁciency of arylsulfatase A enzyme and results
in central and peripheral demyelination [28]. This disorder was
diagnosed in 94 cases (13% out of the 722 patients diagnosed
to have Lysosomal disorders). One hundred and eighteen cases
had low in vitro arylsulfatase-A (ASA) enzyme activity and
close to the carrier levels but with atypical phenotype of
MLD. Those are known as pseudo-deﬁcient cases [29].
4.4.2. Gaucher disease
Gaucher disease results from deﬁciency of b-glucocerebrosid-
ase enzyme [30]. The disorder has three subtypes with differ-
ent clinical manifestations. In type I the patient has
hepatosplenomegaly and hematological and bone manifesta-
tions. In type II the neurological manifestations predominate
with rapidly progressive hepatosplenomegaly while in type III
the patient has milder neurological involvement [30]. In this
study 202 cases [202/1041(19%)] had Gaucher disease which
represents 28% out of the 722 cases diagnosed to have lyso-
somal disorders. They had an age range from infancy to
adulthood with a variation in their clinical presentation. High
percentage of them was recalled to visit our lab after receiv-
ing enzyme replacement therapy in order to measure the
activity of chitotriosidase enzyme in plasma for adjustment
of the enzyme dosage [31–32]. Diagnosis of this treatable dis-
order helps those patients to receive their treatment because
the government offers the treatment to those patients as it
is an expensive one. After receiving the Enzyme Replacement
Therapy (ERT) their general condition, hepatosplenomegaly
and the hematological manifestations were markedly
improved [33].
4.4.3. Niemann–Pick disease (types A and B)
They result from acid sphingomyelinase enzyme deﬁciency
leading to abnormal lysosomal accumulation of sphingomyelin
as the main glycosphingolipid product. The number of patients
proved to have Niemann–Pick disease was 32 cases. Types A
and B of Niemann–Pick disease are mostly differentiated clin-
ically [34]. Niemann–Pick type C syndrome (NPC) has a com-
pletely different cause although it has the same name of
disorder. In this type the sphingomyelinase enzyme has normal
activity and the disease results from a defect in proteins NPC 1
and NPC 2 which are responsible for transporting cholesterol
inside and outside the lysosomes respectively. These proteins
are encoded by two different genes [35]. NPC is diagnosed
by cholesterol study in tissue-cultured ﬁbroblasts [36].
Recently the diagnosis of this type of NP disorder is going
to be offered to the suspected patients in our lab.
4.4.4. The GM2-gangliosidoses
These disorders are very rare as the major stored product in
lysosomes are GM2-gangliosides [37]. They involve two syn-
dromes: Tay-Sachs and Sandhoff. The former syndrome is
due to deﬁcient b-hexosaminidase A and the latter one results
from deﬁciencies in both b-hexosaminidases A and B [38]. In
the present study the suspected cases were subjected to assay
of b-hexosaminidase A and B enzyme activities in their plasma
and 33 (4.6%) of them were diagnosed as having Tay Sacchs
while 8 (1.1%) had Sandhoff syndrome.
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The number of subjects who were suspected to have Krabbe
disorder was the lowest compared to the other IEM among
the included cases and this was shown in the results by the
absence of Krabbe patients in the diagnosed cases [38].
4.4.6. Mucopolysaccharidoses
Mucopolysaccharidoses are the most commonly diagnosed
lysosomal storage disorders among the investigated cases.
Each type of MPS has a broad phenotypic spectrum with a
large range of the age of onset and severity of manifestations.
In the Upper Egypt governorates there were entire families
known to have a certain type of MPS that was inherited in
their off-springs due to the high rate of consanguineous
marriages.
In this study patient groups diagnosed with Hurler Syn-
drome included one hundred cases. They had abnormally high
urinary glycosaminoglycans (GAGs) related to their age and
their two-dimensional electrophoretic separation revealed big
dermatan sulfate and small heparan sulfate spots. The diagno-
sis was conﬁrmed by assaying the speciﬁc deﬁcient enzyme
activity in leukocytes which was completely inactive in severe
cases.
Hunter Syndrome (MPS type II) is the only x-linked form
of MPS disorders although few girls with that syndrome were
recorded [39]. This disease results from a defect in the metab-
olism of dermatan sulfate and heparan sulfate due to deﬁcient
iduronate-2-sulfatase enzyme. Their urinary electrophoretic
pattern of separation is characterized by presence of dermatan
sulfate and heparan sulfate spots. Measuring the enzyme activ-
ity was performed to conﬁrm the diagnosis in 34 patients.
In patients having MPS type III (Sanﬁlippo Syndrome),
signs and symptoms result from a defect in heparan sulfate
metabolism due to deﬁciency in one of four enzymes involved
in its metabolism: heparan sulfamidase (MPS type IIIA),
N-acetylglucosaminidase (MPS type IIIB), glucosamine-N-
acetyltransferase (MPS type IIIC) and N-acetylglucosamine-
6-sulfatase (MPS type IIID) [40]. Diagnosed cases with MPS
type III were 61(17.3% of the diagnosed patients with MPS)
who had a well-deﬁned big heparan sulfate spot separated elec-
trophoretically from their extracted urinary GAGs. Measuring
MPS type IIIB deﬁcient enzyme in blood of suspected cases
conﬁrmed the diagnosis of 22 patients.
Keratan sulfate is one of the six classes of GAGs that is a
major content of connective tissues. Presence of a defect in
its metabolism results in MPS type IV A (Morquio Syndrome)
[41–42]. The presence of the disease was evidenced in 75
patients by the low activity of galactose-6-sulfatase enzyme.
The number of cases diagnosed with Maroteaux–Lamy
Syndrome (MPS type VI) was 83 patients. They had a clinical
course similar to that of Hurler Syndrome except that the
majority of MPS type VI patients had normal intellectual abil-
ities. The pattern of two-dimensional electrophoretic separa-
tion of urinary GAGs showed a big dermatan spot as the
defect is in its metabolism. The conﬁrmation of diagnosis
was based on the assay of arylsulfatase B enzyme activity in
blood which is the defective enzyme in Maroteaux–Lamy Syn-
drome [43].
The purposes of the laboratory testing in biochemical
genetics are to diagnose or exclude inherited metabolic disor-
ders in individual patients where the key metabolite may bequite prominent or to monitor patients who have already been
diagnosed and are receiving treatment designed to avoid accu-
mulation of the key metabolites to toxic concentrations while
ensuring nutritional adequacy. It is also useful for genetic
counseling and prenatal diagnosis for the coming pregnancies
and carrier detection [44]. This study illustrates the experience
of the reference metabolic lab in Egypt over 15 years. The lab
began metabolic disorder screening by using simple diagnostic
techniques like thin layer chromatography and screening
colored tests in urine which by time updated and upgraded
the methods to diagnose a wide range of disorders. This study
shows the most common diagnosed inherited inborn errors of
metabolism among the included Egyptian patients and NBS
programs for the treatable disorders in recommended.
Diagnosis of treatable metabolic disorders improved the
general condition, avoids dangerous complications and even
saves the lives of those patients.
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